Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction
暂无分享,去创建一个
W. März | M. Kleber | H. Scharnagl | G. Delgado | T. Grammer | S. Pilz | A. Tomaschitz | L. Koller | G. Silbernagel | R. Berger | V. Brandenburg | R. Pacher | G. Goliasch | M. Hülsmann | A. Niessner | D. Mörtl | B. Richter | P. Sulzgruber
[1] H. Ulmer,et al. FGF23 is associated with disease severity and prognosis in chronic heart failure , 2014, European journal of clinical investigation.
[2] W. März,et al. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. , 2014, Atherosclerosis.
[3] A. Zwinderman,et al. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. , 2014, JACC. Heart failure.
[4] W. März,et al. C‐reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction , 2014, European journal of heart failure.
[5] J. Pankow,et al. Fibroblast Growth Factor‐23 and Incident Coronary Heart Disease, Heart Failure, and Cardiovascular Mortality: The Atherosclerosis Risk In Communities Study , 2014, Journal of the American Heart Association.
[6] M. Wolf,et al. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease , 2014, Nature Reviews Nephrology.
[7] J. Polak,et al. Fibroblast Growth Factor-23 and Cardiovascular Disease in the General Population: The Multi-Ethnic Study of Atherosclerosis , 2014, Circulation. Heart failure.
[8] A. Go,et al. Fibroblast growth factor-23 and cardiovascular events in CKD. , 2014, Journal of the American Society of Nephrology : JASN.
[9] B. Kestenbaum,et al. Fibroblast Growth Factor–23 and Cardiac Structure and Function , 2014, Journal of the American Heart Association.
[10] N. Ishizaka,et al. Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction , 2014, Heart and Vessels.
[11] B. McManus,et al. Vitamin D in heart failure. , 2013, Journal of cardiac failure.
[12] C. Kovesdy,et al. Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] G. Guyatt,et al. Risk Prediction Models for Mortality in Ambulatory Patients With Heart Failure: A Systematic Review , 2013, Circulation. Heart failure.
[14] M. Wolf,et al. FGF23 Modifies the Relationship Between Vitamin D and Cardiac Remodeling , 2013, Circulation. Heart failure.
[15] M. Kuro-o,et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. , 2013, Annual review of physiology.
[16] Nikolaus Umlauf,et al. Serum phosphate and long-term outcome among patients with stable heart failure. , 2013, Journal of cardiac failure.
[17] J. Ketelslegers,et al. C-terminal FGF23 is a strong predictor of survival in systolic heart failure , 2012, Peptides.
[18] B. Kestenbaum,et al. Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-living Individuals Chs (cardiovascular Health Study) , 2022 .
[19] T. Szekeres,et al. Inorganic phosphate and FGF‐23 predict outcome in stable systolic heart failure , 2012, European journal of clinical investigation.
[20] M. Wolf,et al. UPDATE ON FIBROBLAST GROWTH FACTOR 23 IN CHRONIC KIDNEY DISEASE , 2012, Kidney international.
[21] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[22] L. A. Bonet,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[23] D. Fliser,et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. , 2011, European heart journal.
[24] A. Go,et al. FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.
[25] Michael J. Pencina,et al. Statistical methods for assessment of added usefulness of new biomarkers , 2010, Clinical chemistry and laboratory medicine.
[26] Roger Newson,et al. Comparing the Predictive Powers of Survival Models Using Harrell's C or Somers’ D , 2010 .
[27] R. D'Agostino,et al. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community , 2010, European journal of heart failure.
[28] L. Schurgers,et al. The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.
[29] H. Melhus,et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. , 2009, Atherosclerosis.
[30] Thomas J. Wang,et al. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease , 2009, Circulation.
[31] G. Novo,et al. Biomarkers in heart failure. , 2009, Frontiers in bioscience.
[32] K. Dickstein,et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.
[33] S. Russell,et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. , 2007, Journal of the American Society of Nephrology : JASN.
[34] M. Pfeffer,et al. Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease , 2005, Circulation.
[35] B. Yawn,et al. Trends in heart failure incidence and survival in a community-based population. , 2004, JAMA.
[36] W. März,et al. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. , 2001, Pharmacogenomics.
[37] S. Anker,et al. Metabolic, functional, and haemodynamic staging for CHF? , 1996, The Lancet.